The test, priced at $689, can detect over 50 types of cancer, including pancreatic, ovarian, and lung cancers. Despite this innovation, several analyst firms have adjusted their price targets for ...

Investing.com - Benchmark raised its price target on Exact Sciences (NASDAQ:EXAS) to $60.00 from $54.00 on Tuesday, while maintaining a Buy rating on the stock. Currently trading at $53.86, the ...

Objective: to verify validity evidence for the Praxis Model for Technology Development ® in nursing. Method: a methodological study, guided by the human praxis framework. The operational model content ...

The new iPhones Apple unveiled last week offer improved battery life, at least according to official estimates. Better battery life is something buyers expect from each new iPhone generation.

Exact Sciences CEO and Chair Kevin Conroy discusses the company's new multi-cancer blood test and competitive environment. Speaking on "Bloomberg Open Interest," Conroy also comments on President ...

After nearly a decade of research and development, a Madison company is launching an innovative blood test that can detect cancers. Exact Sciences Corp., the maker of Cologuard, a home collection kit ...

Consumers can now purchase Exact Sciences’ liquid biopsy early detection test, Cancerguard, and get an indication of whether they might have one of 50 different cancers included in the test’s analysis ...

(RTTNews) - Exact Sciences Corp. (EXAS) announced the U.S. launch of Cancerguard™, its multi-cancer early detection or MCED blood test, now available as a laboratory-developed test or LDT. Cancerguard ...

Nearly 70 percent of annual cancer cases and deaths in the U.S. occur in cancers with no recommended screening.1,2,3 The Cancerguard test can help address the unmet need by complementing existing ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer diagnostics, today announced the launch of the Cancerguard™ test, a new multi-cancer early detection (MCED) ...